SCHEMBL7018502

SCHEMBL7018502

Cc1ccccc1-c1cc(-n2cnc3cc(-c4ccnc(N)n4)ccc32)nc(N[C@@H](C)c2ccc(F)c(F)c2F)n1

nearest known ligand 0.58

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LCK P06239 12/20 0.58
CYP3A4 P08684 2/20 0.39
PLK1 P53350 2/20 0.39
PLK3 Q9H4B4 1/20 0.39
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HTT P42858 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ROCK1 Q13464 1/20 0.33
JAK2 O60674 1/20 0.33
JAK3 P52333 1/20 0.33
FEN1 P39748 2/20 0.32
MAPK14 Q16539 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7018679 0.90 LCK (0.55) LCKCYP3A4PLK1PLK3KDM4E
SCHEMBL7575747 0.87 LCK (0.76) LCKCYP3A4PLK1PLK3KDM4E
SCHEMBL7016254 0.87 LCK (0.76) LCKCYP3A4PLK1PLK3KDM4E
SCHEMBL7024612 0.81 LCK (0.70) LCKCYP3A4PLK1PLK3KDM4E
SCHEMBL7016544 0.80 LCK (0.61) LCKCYP3A4PLK1PLK3KDM4E
SCHEMBL7500919 0.77 LCK (0.54) LCKKDM4EALDH1A1HTTRAB9A
SCHEMBL7568847 0.77 LCK (0.71) LCKCYP3A4PLK1PLK3KDM4E
SCHEMBL7020588 0.77 LCK (0.71) LCKCYP3A4PLK1PLK3KDM4E
SCHEMBL7576852 0.74 LCK (0.71) LCKJAK2JAK3
SCHEMBL7019097 0.74 LCK (0.71) LCKJAK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1206265-B1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2003-11-12 EP claimed
US-6498165-B1 PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS MERCK & CO., INC. 2002-12-24 US claimed
EP-1206265-A4 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2002-08-07 EP claimed
EP-1206265-A1 SRC KINASE INHIBITOR COMPOUNDS Merck & Co., Inc. (US) 2002-05-22 EP claimed
WO-2001000213-A1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO., INC. (US) 2001-01-04 WO claimed
EP-1206265-B1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2003-11-12 EP disclosed
US-6498165-B1 PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS MERCK & CO., INC. 2002-12-24 US disclosed
EP-1206265-A4 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2002-08-07 EP disclosed
EP-1206265-A1 SRC KINASE INHIBITOR COMPOUNDS Merck & Co., Inc. (US) 2002-05-22 EP disclosed
WO-2001000213-A1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO., INC. (US) 2001-01-04 WO disclosed